MDB-27. A PRO-DRUG OF TRIPTOLIDE IN CLINICAL DEVELOPMENT ATTENUATES HIGH-RISK MEDULLOBLASTOMA GROWTH

por Rodriguez-Blanco, Jezabel, Salvador, April, Suter, Robert, Palomo-Caturla, Isabel, Viera, Megan, Nienhius, Ashley Metts, Ayad, Nagi, Robbins, David
Publicado 2023

Noncanonical activation of GLI signaling in SOX2(+) cells drives medulloblastoma relapse

por Swiderska-Syn, Marzena, Mir-Pedrol, Júlia, Oles, Alexander, Schleuger, Olga, Salvador, April D., Greiner, Sean M., Seward, Cara, Yang, Fan, Babcock, Benjamin R., Shen, Chen, Wynn, Daniel T., Sanchez-Mejias, Avencia, Gershon, Timothy R., Martin, Vanesa, McCrea, Heather J., Lindsey, Kathryn G., Krieg, Carsten, Rodriguez-Blanco, Jezabel
Publicado 2022